Alzheimer’s drug

The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.

A clot-busting drug administered during a stroke helped lead to the death of a patient taking the experimental Alzheimer’s drug lecanemab, a peer-reviewed autopsy analysis has revealed.

COVID hospitalizations approach last summer’s high, but flu and RSV cases waning … NC nursing home to pay $126K after storm-related staff shortages, two patient deaths … FDA decision on experimental...

An “atypical review process and corporate greed” factored into the FDA’s approval of Alzheimer’s drug Aduhelm in 2021, congressional investigators say. They recommend sticking to protocol...

Only two days left to nominate a deserving colleague for a McKnight’s Woman of Distinction 2023 award! … Third death tied to Eisai and Biogen’s experimental Alzheimer’s drug lecanemab … U.S....

The experimental Alzheimer’s drug slowed decline in memory and thinking by 27% when compared with placebo, although 20% of patients reported adverse events. 

Two drugs in late-stage clinical trials are making news, one as a potential treatment for agitation, and the other for evidence of bleeding risk.

News that Alzheimer’s drug lecanemab has reduced cognitive decline by 27% is receiving measured responses from prescribers as they await further data.

The Medicare coverage proposal for these drugs is too restrictive, limiting potential benefits to a select few, the two congressmen argue in a letter sent Monday to HHS Secretary Xavier Becerra.

U.S. Secretary of Health and Human Services Xavier Becerra on Monday ordered Medicare to reassess a big premium increase facing millions of seniors this year, after an expensive new Alzheimer’s drug...